Study of dose escalation and sequence switching of administration of the combination of docetaxel and doxorubicin in advanced breast cancer

Clinical Cancer Research

Volumn 6, Issue 10, 2000, Pages 4082-4090

  Itoh, Kuniaki ^a   Sasaki, Yasutsuna ^a   Fujii, Hirofumi ^a   Minami, Hironobu ^a   Ohtsu, Tomoko ^a   Wakita, Tomoko ^a   Igarashi, Tadahiko ^a   Watanabe, Yuko ^a   Onozawa, Yusuke ^a   Kashimura, Masaki ^b   Ohashi, Yasuo ^c  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b Rhône Poulenc Rorer Japan Inc   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; DOXORUBICINOL; FLUOROURACIL;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GRADING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CROSSOVER PROCEDURE; DIARRHEA; DOSE RESPONSE; DRUG TOLERANCE; HUMAN; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; TREATMENT PLANNING;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; BREAST NEOPLASMS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEMALE; HUMANS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEUTROPENIA; PACLITAXEL; TAXOIDS; TIME FACTORS;

EID: 0033765492     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Docetaxel
2. Docetaxel as single-agent therapy in metastatic breast cancer: Clinical efficacy
3. Chemotherapy and survival in advanced breast cancer: The inclusion of doxorubicin in Cooper type regimens
4. Sequences of Taxol and cisplatin: A Phase I and pharmacologic study
5. Sequences of topotecan and cisplatin: Phase I, pharmacologic, and in vitro studies to examine sequence dependence
6. Phase I and pharmacologic study of sequences of paclitaxel and cyclophosphamide supported by granulocyte colony-stimulating factor in women with previously treated metastatic breast cancer
7. Sequence-dependent hematological toxicity associated with the 3-hour paclitaxel/cyclophosphamide doublet
8. Phase I study of paclitaxel in combination with cyclophosphamide and granulocyte colony-stimulating factor in metastatic breast cancer patients
9. Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer
10. Phase I and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: A gynecologic oncology group study
11. Hepatic biotransformation of docetaxel (Taxotere) in vitro: Involvement of the CYP3A subfamily in humans
12. Phase I clinical trial of RP56976 (docetaxel); a new anticancer drug
13. Determination of Taxotere in human plasma by a semi-automated high-performance liquid chromatographic method
14. Estimation of doxorubicin and doxorubicinol by high-performance liquid chromatography and advanced automated sample processor
15. A pharmacokinetic analysis program (MULTI) for microcomputer
16. Paclitaxel (Taxol)/doxorubicin combinations in advanced breast cancer: The Eastern Cooperative Oncology Group experience
17. Pharmacokinetics of Taxol and doxorubicin administered alone and in combination by continuous 72-hour infusion
18. Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a Phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer
19. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer
20. Drug interactions with the taxanes
21. Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors
22. Docetaxel (D) pharmacokinetics (PK): Influence of coadministered drugs in Phase I combination studies
23. Taxotere (T) does not change the pharmacokinetic (PK) profile of doxorubicin (Dox) and doxorubicinol (Dx-ol)
24. Taxoids in combination with anthracyclines and other agents: Pharmacokinetic considerations
25. Pharmacokinetic interactions of paclitaxel, docetaxel and their vehicles with doxorubicin
26. Docetaxel in combination chemotherapy for metastatic breast cancer
27. Review of docetaxel/doxorubicin combination in metastatic breast cancer
28. Phase I and pharmacologic (PK) study of docetaxel and doxorubicin in patients (pts) with solid tumors: Dose limiting toxicity at the first dose level
29. Population pharmacokinetics of docetaxel in Japanese patients
30. Population pharmacokinetics/pharmacodynamics of docetaxel in Phase II studies in patients with cancer